Ardelyx, Inc.
ARDX

$1.17 B
Marketcap
$4.92
Share price
Country
$0.20
Change (1 day)
$10.13
Year High
$4.06
Year Low
Categories

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

marketcap

Revenue of Ardelyx, Inc. (ARDX)

Revenue in 2023 (TTM): $124.46 M

According to Ardelyx, Inc.'s latest financial reports the company's current revenue (TTM) is $124.46 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history of Ardelyx, Inc.

Annual Revenue

Year Revenue Gross Profit Ebitda Income Before Tax Net Income
2023 $124.46 M $106.66 M $-55,354,000 $-65,520,000 $-66,067,000
2022 $52.16 M $48.04 M $-60,982,000 $-67,199,000 $-67,207,000
2021 $10.1 M $9.1 M $-150,852,000 $-158,161,000 $-158,165,000
2020 $7.57 M $7.43 M $-85,241,000 $-94,311,000 $-94,313,000
2019 $5.28 M $4.68 M $-84,571,000 $-94,637,000 $-94,940,000
2018 $2.61 M $2.14 M $-85,082,000 $-91,294,000 $-91,298,000
2017 $42 M $33.6 M $-60,520,999 $-63,160,000 $-64,339,000
2016 $24.03 M $22.73 M $-111,600,000 $-112,387,000 $-112,387,000
2015 $24.03 M $23.2 M $-28,560,000 $-29,650,000 $-29,621,000
2014 $31.62 M $5.72 M $-1,262,000 $-3,147,000 $-3,214,000
2013 $28.93 M $835 K $-2,273,000 $-6,423,000 $-6,564,000
2012 $5.41 M $3.5 M $-8,130,000 $-9,785,000 $-9,785,000